中轴型脊椎关节炎市场：KOL 洞察

本报告深入分析了中轴型脊椎关节炎（axSpA）治疗的现状和未来方向，重点关註生物製剂和管道疗法的使用。这篇综述研究了抗肿瘤坏死因子（TNF）抑制剂作为非类固醇抗发炎药物（NSAID）之后的一线治疗的应用、白细胞介素 17（IL-17）抑製剂（例如 Cosentyx、Taltz 和 Bimbopag）的定位，以及 Janus 激酶（JAK）抑製剂（例如 Xeljanz 和 Rinboq）的合理使用。全面了解当前治疗策略和 axSpA 管理的新兴趋势。

报告内容

• 抗 TNF 药物目前如何用于治疗 axSpA？
• 抗 TNF 生物相似药如何影响 axSpA 治疗？
• Cosentyx、Taltz 和 Vimzerex 等 IL-17 抑制剂在治疗演算法中处于什么位置？
• 长期研究如何影响 IL-17 处方趋势？
• Rinvoq 和 Xeljanz 等 JAK 抑制剂在 axSpA 治疗模式中处于什么位置？
• ORAL 监测研究是否影响 JAK 抑制剂的处方？
• Jyseleca 在 axSpA 市场有潜力吗？它有什么可展示的？
• 目前在 axSpA 诊断和治疗方面尚未满足的需求
• 未来 3-5年，axSpA 的治疗演算法将如何发展？

主要品牌

This report provides an in-depth analysis of the current landscape and future directions in the treatment of axial spondyloarthritis (axSpA), focusing on the use of biologic and pipeline therapies. It examines the use of anti-tumour necrosis factor (TNF) inhibitors as the first-line treatment following non-steroidal anti-inflammatory drugs (NSAIDs), the positioning of interleukin-17 (IL-17) inhibitors, such as Cosentyx, Taltz, and Bimzelx, and the cautious use of Janus kinase (JAK) inhibitors like Xeljanz and Rinvoq. Gain a comprehensive overview of current treatment strategies and emerging trends in axSpA management.

Key Questions Answered:

• How are anti-TNFs currently used in axSpA treatment lines?
• What impact have anti-TNF biosimilars had on axSpA treatment?
• How are IL-17 inhibitors like Cosentyx, Taltz, and Bimzelx positioned in treatment algorithm?
• How have long-term trials influenced IL-17 prescription trends?
• Where do JAK inhibitors like Rinvoq and Xeljanz fit in the axSpA treatment paradigm?
• Has the ORAL Surveillance study affected JAK inhibitor prescriptions?
• Does Jyseleca have potential in the axSpA market, and what must it demonstrate?
• What are the current unmet needs in axSpA diagnosis and treatment?
• How will the axSpA treatment algorithm evolve over the next three to five years?

Key Brands:

Partial List of Participating Experts:

• Associate Professor of Medicine, Director of Yale Spondyloarthritis Program and Co-chair, Safety and Quality Council at Yale School of Medicine, CT
• Assistant Professor of Medicine, Brigham and Women's Hospital, MA
• Clinical Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Co-Director of the Division of Rheumatology at Presbyterian Hospital, Dallas, TX
• Director of the Leeds NIHR Biomedical Research Centre, Professor of Rheumatology, University of Leeds, Leeds, UK
• Full Professor of Rheumatology at the Department of Medicine and Health Sciences "Vincenzo Tiberio" and Head of the Internal Medicine and Rheumatology Unit at the University of Molise in Campobasso, Italy
• Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC and Director of the Amsterdam Rheumatology and Immunology Center ARC in Amsterdam, Netherlands

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.